E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Uveitis of the Posterior Segment of the Eye. |
|
E.1.1.1 | Medical condition in easily understood language |
Active non-infectious posterior, intermediate or pan-uveitis. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Ocular Physiological Phenomena [G14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036370 |
E.1.2 | Term | Posterior uveitis |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and efficacy of intravitreal injection of 440 μg DE-109 as compared with 44 μg DE-109 for the treatment of active, noninfectious uveitis of the posterior segment of the eye. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety of intravitreal injection of 880 μg DE-109 as compared to 44 μg DE-109 for the treatment of active, non-infectious uveitis of the posterior segment of the eye. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Ability to give informed consent and attend all study visits 2. Males or females greater than or equal to 18 years of age 3. Have diagnosis of active uveitis of the posterior segment determined by the Investigator to be noninfectious based on the subject's medical history, history of present illness, ocular examination, review of systems, physical examination, and any relevant, pertinent laboratory evaluations. If an anterior component is present, it must be less than the posterior component 4. Have active uveitis defined as a >1+ (excluding 1+) VH score (modified SUN scale) in the study eye 5. Best-corrected ETDRS visual acuity letter score of 19 letters or more (20/400 Snellen equivalent or better) in study eye 6. Female participants of childbearing potential must not be pregnant or breast-feeding, have a negative pregnancy test at Screening and must be willing to undergo pregnancy tests throughout the study 7. Both female participants of childbearing potential and male participants able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, must abstain from intercourse or must agree to practice acceptable methods of contraception throughout the course of the study 8. Subjects must have vision ≥ 20/200 in the non-study eye |
|
E.4 | Principal exclusion criteria |
Ocular: 1. Active infectious uveitis. However, if the uveitis is the consequence of a previous infectious disease, such as Tuberculosis, the previous infectious disease must be confirmed as no longer active 2. Clinically suspected or confirmed central nervous system or ocular lymphoma 3. Primary diagnosis of anterior uveitis 4. Uncontrolled glaucoma, evidenced by an intraocular pressure of > 21 mmHg while on medical therapy, or chronic hypotony (<6 mmHg) 5. Any implantable corticosteroid-eluting device (e.g. Ozurdex, I-vation, Iluvien, triamcinolone acetonide [TA] intravitreal implant) in the study eye: a. If the Investigator confirms the device has no demonstrable efficacy as indicated in the package insert, the subject will be eligible; b. If a Medidur implant Iluvien or Retisert has, it should have been implanted no less than 3 years and 90 days prior to Day 1, the subject will be eligible 6. Any significant ocular disease that could compromise vision in the study eye. These include, but are not limited to: a. Diabetic retinopathy: proliferative diabetic retinopathy (PDR) or nonproliferative diabetic retinopathy (NPDR) that compromise vision. Subjects with NPDR or PDR that does not compromise vision are not excluded from the study; b. Wet age-related macular degeneration; c. Myopic degeneration with active subfoveal choroidal neovascularization 7. Lens opacities or obscured ocular media other than vitreous haze upon enrollment such that reliable evaluations and grading of the posterior segment cannot be performed 8. Intraocular surgery within 90 days prior to Day 1 in the study eye 9. Capsulotomy within 30 days prior to Day 1 in the study eye 10. Any of the following treatments within 90 days prior to Day 1 or anticipated use of any of the following treatments to the study eye: a. Intravitreal injections (including but not limited to steroids or antivascular endothelial growth factors); b. Posterior subtenon steroids 11. Ocular or periocular infection in either eye 12. Pupillary dilation inadequate for quality stereoscopic fundus photography in the study eye 13. Media opacity that would limit clinical visualization, intravenous fluorescein angiography (IVFA), or OCT evaluation in the study eye 14. History of herpetic infection in the study eye or adnexa 15. Presence of known active, inactive toxoplasmosis or toxoplasmosis scar in either eye 16. Presence of any form of ocular malignancy in either eye including choroidal melanoma 17. History of vitrectomy in the study eye Non-Ocular: 1. Allergy or hypersensitivity to study drug product or fluorescein dye or other study related procedures/medications 2. Participation in other investigational drug or device clinical trials within 30 days prior to Day 1, or planning to participate in other investigational drug or device clinical trials for the entire duration of the study. This includes both ocular and non-ocular clinical trials. 3. Treatment with a monoclonal antibody or any other biologic therapy (i.e. Etanercept, Tocilizumab, Adalimumab, Rituximab, etc.) within the previous 30 days, or with alemtuzumab within the previous 12 months from Day 1 4. Immunosuppressive therapy (e.g., methotrexate, cyclosporine, cyclophosphamide, chlorambucil, mycophenolate mofetil, tacrolimus, azathioprine or colchicine) other than prednisone or other corticosteroids for the treatment of uveitis within 30 days of the first study drug administration (Day 1) 5. Any recent systemic infection within 30 days of Screening 6. Known to be immunocompromised 7. History of cytomegalovirus infection or clinical evidence of active cytomegalovirus infection at Screening and/or Day 1 8. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease condition that contraindicates the use of an investigational drug, might affect the interpretation of the results of the study, or renders the subject at high risk for treatment complications 9. Malignancy in remission for less than 5 years prior to study participation (except basal cell or squamous cell skin cancer, or treated melanoma of the skin less than 24 months since last treatment) 10. Females who are pregnant or lactating and females of child-bearing potential who are not using adequate contraceptive precautions (i.e., intrauterine device, oral contraceptives, barrier method, or other contraception deemed adequate by the Investigator) 11. Use of medically prescribed marijuana or other illegal medication 12. Active systemic sarcoidosis within the last 30 months (i.e. Subjects with uveitis secondary to sarcoidosis will be eligible as long as systemic sarcoidosis is not active and systemic immunosuppressive therapy has not been given in the last 30 months) In addition, the Investigator or Santen Medical Monitor may declare a subject ineligible for any sound reason. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Vitreous haze (VH) 0 response: Having a VH score of 0 at Month 5 based on the modified Standardized Uveitis Nomenclature (SUN) Photographic scale.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Key Secondary Endpoints: • VH 0 or 2-unit response: Having a VH score of 0 or a decrease (improvement) of at least 2 units from baseline in VH score at Month 5(modified SUN scale) • VH 0 or 0.5+ response: Having a VH score of 0 or 0.5+ at Month 5 (modified SUN scale) • Corticosteroid tapering success (for the Intent-to-Taper Population): The overall prednisoneequivalent dose being tapered off to ≤ 5 mg/day at Month 5. Other Secondary Endpoints: • VH 0 response at Month 6: Having a VH score of 0 at Month 6 (modified SUN scale) • VH 0 or 2-unit response at Month 6: Having a VH score of 0 or a decrease (improvement) of at least 2 units from baseline in VH score at Month 6 (modified SUN scale) • VH 0 or 0.5+ response at Month 6: Having a VH score of 0 or 0.5+ at Month 6 (modified SUN scale) • Change from baseline in VH score at Month 5 (modified SUN scale) • Change from baseline in VH score at Month 6 (modified SUN scale) • Change from baseline in best-corrected visual acuity (BCVA) at Month 5 • Change from baseline in central retinal thickness at Month 5 as measured by optical coherence tomography (OCT) • Change from baseline in the National Eye Institute (NEI) Visual Functioning Questionnaire-25 (VFQ-25) composite score at Month 5 • Use of rescue therapy before Month 5 • Time to rescue from randomization before Month 5 Other secondary endpoints such as "time to VH score of 0 before Month 5", "having an increase (improvement) of at least 15 letters in BCVA from baseline at Month 5", and the same set of endpoints at Month 6 that are not listed may also be analyzed for exploratory purposes. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Open label treatment with 880 ug DE-109 after month 5 |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 57 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Austria |
Brazil |
Chile |
Colombia |
Dominican Republic |
France |
Germany |
India |
Israel |
Italy |
Mexico |
Peru |
Poland |
Spain |
Turkey |
United Kingdom |
United States |
United States Minor Outlying Islands |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last patient |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |